CONCLUSIONS: This is the first study to demonstrate safety and efficacy of intravesical incobotulinumtoxin A in patients with neurogenic or idiopathic detrusor overactivity. Incobotulinumtoxin A may be an attractive alternative to onabotulinumtoxin A, especially given its lower cost. Small sample size limits this data, however early results suggest improvements in quality of life and bladder dynamics. A larger, prospective study will be required to validate these findings.
INTRODUCTION AND OBJECTIVES: Following spinal cord injury (SCI), disruption to neuronal pathways of the bladder can lead to neurogenic detrusor over-activity (NDO) causing reduced capacity, high pressure and incontinence. Intra-detrusor injections of botulinum toxin A (BTX-A) are commonly used to manage these complications. Between 2013-2014 our department changed from using abobotulinum toxin (aboBTX) (750-1000 u) to onabotulinum toxin (onaBTX) (200 u) . We have analysed the urodynamic outcomes and patient satisfaction to determine the relative efficacy of the two drugs on NDO following SCI.
METHODS: The medical notes of 171 patients receiving consecutive doses of aboBTX and onaBTX during 2013-2014 were reviewed. 36 SCI patients with NDO and urodynamics within 6 months of injection of both aboBTX and onaBTX were included. The maximum cystometric capacity (MCC) and maximum detrusor pressure (MDP) were recorded. Paired t-tests were performed to test difference in bladder function between the two BTX-A drugs.
RESULTS: The post-injection mean (AE SD) MCC for aboBTX was 375 AE 178 ml and for onaBTX was 378 AE 212 ml. The post injection mean (AE SD) MDP for aboBTX was 25 AE 21 cmH 2 O and for onaBTX was 27 AE 18 cmH 2 O. There was no significant difference between MCC (p¼0.5) and MDP (p¼0.86) for each drug. The scatter graphs demonstrate the relationship between the preparations with respect to MCC and MDP. The solid line represents the linear regression and the dashed line represents a 1:1 relationship. The linear regression for MCC had a slope of 1 demonstrating a clear correlation between the bladder capacity after aboBTX and onaBTX. There was not such a clear correlation between the MDP data. 12 out of 36 patients reported worse satisfaction with onaBTX than aboBTX, though interestingly this did not correlate with worse urodynamic outcomes.
CONCLUSIONS: There was no statistically significant difference in objectively measured urodynamic parameters of bladder function between aboBTX and onaBTX in patients with NDO following SCI. However 1/3 of patients reported worse satisfaction with onaBTX. The data will be further analysed to compare the efficacy of repeated injections and the effect of prior exposure to each agent.
Source of Funding: None

MP85-17 FACTORS ASSOCIATED WITH DURABILITY OF THERAPEUTIC BOTULINUM TOXIN A INJECTION FOR OVERACTIVE BLADDER
Kristian Stensland*, Burlington, MA; Jay Vance, Bennett Sluis, Boston, MA; Jared Schober, Arthur Mourtzinos, Lara Maclachlan, Burlington, MA INTRODUCTION AND OBJECTIVES: Patients suffering from overactive bladder (OAB) without response to behavioral and pharmaceutical intervention may opt for third-line therapy with botulinum toxin A injection. Botulinum injections have shown success in treating OAB urinary symptoms, but require repeat injections at an interval of 4-12 months. This study seeks to identify factors associated with the durability of this therapeutic effect.
METHODS: Patients undergoing treatment for OAB at Lahey Hospital and Medical Center between 2004 and 2016 were identified. Demographic, clinical and treatment data were extracted from patient charts. Patients were included if they had at least 1 botulinum injections. Time from initial to second botulinum injection was defined as therapeutic durability; time from initial injection to last clinic follow-up was defined and time to event analyses were employed: univariate analysis via log-rank method and multivariate Cox proportional hazards were used to identify associations with therapeutic durability. The multivariate Cox model comprised univariate factors with p values below 0.1 and a priori clinical variables. Significance was defined at the a¼ 0.05 level.
RESULTS: Of the available patients, 54 patients met inclusion criteria. Median time to repeat injection for those who had a second injection was 259 days (8.6 months). Kaplan-Meier survival estimated that 50% of patients required reinjection at 330 days (11 months). On univariate analysis, history of spinal cord injury (p ¼ 0.041), prostate cancer (p < 0.001), history of stroke/CVA (p¼0.037), and history of UTI (p¼0.013) were significantly associated with lower therapeutic durability. On multivariate analysis, only prostate cancer (OR 50.2, 95% CI 2.95-854, p ¼ 0.0068) and history of UTI (OR 4.11, 95% CI 1.10-15.3, p ¼ 0.035) were associated with lower therapeutic durability.
CONCLUSIONS: Botulinum injection showed a median durability of roughly 9 months. Patients with prostate cancer or a history of UTI had a statistically significantly lower durability of botulinum injection. Further study is warranted to identify further etiologic origins of these connections or elucidate other associated cofactors. RESULTS: Of 268 patients in the OAB database, 128 patients met inclusion criteria. Within the male subgroup, 26 of 47 men (44.7%) had successful treatment, compared to 73 of 81 women (90.1%). Within the male group, the factors significantly associated with SNS failure were mean volume at first urge on UDS (80.5ml in SNS failure vs. 126.5ml in SNS success) and smoking (SNS failure more likely to be current smokers, p ¼ 0.039). Similarly, on multivariate analysis only lower volume at first urge was statistically significantly associated with SNS failure (OR¼.97, 95%CI 0.94-0.99). Within the female group, there were no statistically significant associations between measured variables and SNS success. Notably, mean volume at first urge on UDS was not statistically significantly associated with SNS failure, though there was a similarly large difference between groups (97.5ml in SNS failure compared to 136.0ml in SNS success). On multivariate analysis in the female group, there were no significant factors associated with SNS success.
Source of
CONCLUSIONS: SNS is frequently successful at relieving OAB symptoms. The rate of success in men is significantly lower than in women, suggesting that SNS implantation is more effective in woman than men. The best predictor of success for male patients in this study was higher volume at first urge on UDS. Further study is needed to evaluate other predictors of SNS success and to further characterize differentiating characteristics between male and female patients with respect to overactive bladder treatment.
Source of Funding: None
MP85-19 SIDE MATTERS: SACRAL NEUROMODULATION LEAD PLACEMENT ON THE LESS VERSATILE SIDE OFFERS GREATER BENEFIT IN PATIENTS WITH ASYMMETRY
Usama Al-Qassab*, Lindsey Hartsell, Joy Butterworth, John DeCaro, Atlanta, GA; Niall Galloway, Atlanta , GA INTRODUCTION AND OBJECTIVES: Sacral neuromodulation with InterstimTM (Medtronic) is a highly successful treatment for both non-obstructive urinary retention as well as for overactive bladder (OAB) symptoms, but the mechanism of action is not yet defined. Importantly, attempts to predict and improve outcomes have been inconsistent. In this study we assessed the association between laterality of lead placement and patient asymmetry. We have recognized patterns of asymmetry in our patients with severe voiding symptoms. We hypothesize a higher success with lead placement on the less formed side.
METHODS: We performed an IRB approved retrospective chart review of InterstimTM placements from 2003 to 2013. A total of 57 patients were identified, and who had undergone first-stage lead placement for non-obstructive urinary retention or OAB. Patient symmetry was assessed by preoperative physical examination findings of bilateral sacral sensory function, gluteal muscle mass, intrinsic muscles of the feet, and pelvic floor muscle strength. Asymmetry was defined as a significant, consistent lateralized difference in findings based on one observer. Among asymmetric patients the side determined to have diminished function was deemed less versatile. Subtle findings were considered symmetric. Successful lead placement was regarded as a 50% or greater improvement in urinary symptoms and transition to second stage InterstimTM placement.
RESULTS: Of the 57 patients reviewed, 47 (82%) progressed to successful second stage InterStimTM placement while 10 (18%) failed. A majority, 39/57(67%) of patients were deemed asymmetric and of these 33 (84%) progressed to second stage. Of the 18 symmetric patients success was achieved in 14 (78%). In a subgroup analysis of 19 asymmetric patients who underwent an initial trial of bilateral lead placements, 13 reported greater benefit with the lead placed on the less versatile side, 2 were equivocal, and only 4 favored the more versatile side (p¼0.003).
CONCLUSIONS: Asymmetry is a very frequent finding in patients with pelvic floor dysfunction. Lead placement on the less versatile side of asymmetric patients correlated with better InterstimTM success. Determination of asymmetry among InterStimTM candidates should be considered during preoperative evaluation to guide the choice of side for lead placement.
Source of Funding: none
MP85-20 ACYLOXYACYL HYDROLASE MODULATES PELVIC PAIN SEVERITY
Wenbin Yang*, Ryan Yaggie, Mingcheng Jiang, Charles Rudick, Joseph Done, Charles Heckman, Anthony Schaeffer, David Klumpp, Chicago, IL INTRODUCTION AND OBJECTIVES: Chronic pelvic pain causes significant morbidity to patients and is a bane to clinicians. Using a murine neurogenic cystitis model that recapitulates key aspects of interstitial cystitis/bladder pain syndrome (IC), we recently showed that pseudorabies virus (PRV) induces severe pelvic allodynia BALB/c mice, relative to C57BL/6 mice. Here, we use a genetic strategy to identify a novel modulator of pelvic pain expressed along the bladderbrain axis.
METHODS: Mouse SNP genotyping: We generated 96 F2 female mice, infected with PRV, and pelvic pain was scored in response to von Frey filament stimulus. Purified F2 mouse tail DNA was genotyped with Illumina Mouse MD arrays containing 1449 SNPs. We mapped QTL using R/qtl software. Knockout mice were evaluated for pelvic allodynia, and expression was localized by immunofluorescence.
RESULTS: female F1CxB mice exhibit the low-allodynia phenotype of C57BL/6 parental mice in response to PRV, indicating that the severe pelvic pain phenotype of BALB/c mice is recessive. To identify loci modulating pelvic pain, we performed a quantitative trait locus (QTL) analysis on female F2CxB progeny by quantifying PRVinduced allodynia and statistical associations between pelvic pain and recombinant genotypes. Analyses identified a polymorphism on chromosome 13, rs6314295, significantly associated with allodynia (LOD¼3.11). Expression analyses revealed that the mouse gene for acyloxyacyl hydrolase (AOAH), encoded near this SNP, was induced in the sacral spinal cord of PRV-infected mice. AOAH-deficient mice exhibited pelvic hypersensitivity compared to wild-type (WT) mice and developed extreme pelvic allodynia both in neurogenic and bacterial cystitis models. AOAH deficiency results in greater bladder pathology in neurogenic cystitis consistent with increased bladder mast cell activation. AOAH expression was detected along the bladder-brain axis, and AOAH-deficient mice have elevated levels of bladder VEGF, a UCPPS biomarker.
CONCLUSIONS: These findings indicate that AOAH is expressed along the bladder-brain axis and modulates pelvic pain severity and UCPPS biomarker expression. Thus, allelic variation in Aoah may mediate susceptibility to UCPPS symptoms.
